Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T05:30:37.368Z Has data issue: false hasContentIssue false

30 - Gastric Cancer Metastasis

from PART II - CLINICAL RESEARCH

Published online by Cambridge University Press:  05 June 2012

By
Takako Eguchi Nakajima  and
Yasuhide Yamada
Edited by
David Lyden ,
Danny R. Welch  and
Bethan Psaila
Takako Eguchi Nakajima
Affiliation:
National Cancer Center Hospital, Japan
Yasuhide Yamada
Affiliation:
National Cancer Center Hospital, Japan
David Lyden
Affiliation:
Weill Cornell Medical College, New York
Danny R. Welch
Affiliation:
Weill Cornell Medical College, New York
Bethan Psaila
Affiliation:
Imperial College of Medicine, London
Get access

Summary

The treatment outcome of gastric cancer has markedly improved with the advancement of diagnostic technology, widespread use of radical resection combined with lymph node dissection, and advances in chemotherapy. However, these results must be improved as about 700,000 people worldwide die from gastric cancer annually. Therefore, elucidation of the metastatic mechanism of gastric cancer, prevention and early detection of metastasis, and development of drugs based on the metastatic mechanism are important for achieving optimal treatment outcome.

CLINICAL FEATURES OF GASTRIC CANCER METASTASIS

There are two major forms of gastric cancer in terms of clinical metastasis. In histologically scirrhous gastric cancer, which is composed primarily of poorly differentiated adenocarcinoma/signet ring carcinoma, a large amount of interstitial component is morphologically observed, and cancer cells single-handedly assume the course of diffuse invasion. This type of gastric cancer spreads by the peritoneal or the lymph node metastatic route. In histologically nonscirrhous gastric cancer, the main presenting histological features are those of well- or moderately differentiated adenocarcinoma. In this form, cancer cells frequently invade vascular channels as tumor cell clusters (or tumor cell clumps) and spread to distant organs (hematogenous metastasis).

Lymph node metastasis is diagnosed by computed tomography, magnetic resonance imaging, endoscopic ultrasound, or positron emission tomography, but the sensitivity and specificity of these techniques are insufficient. The need for and the extent of lymph node dissection, as well as the significance of and treatment protocol for micrometastasis (MM) in lymph node metastasis, remains debatable.

Type
Chapter
Information
Cancer Metastasis
Biologic Basis and Therapeutics
 , pp. 325 - 332
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Koizumi, W, Narahara, H, Hara, T et al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9: 215–21.CrossRefGoogle ScholarPubMed
Cunningham, D, Allum, WH, Stenning, SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355: 11–20.CrossRefGoogle ScholarPubMed
Oda, T, Kanai, Y, Oyama, T et al. (1994) E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA. 91: 1858–62.CrossRefGoogle ScholarPubMed
Macdonald, JS, Smalley, SR, Benedetti, J et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345: 725–30.CrossRefGoogle ScholarPubMed
Sakuramoto, S, Sasako, M, Yamaguchi, T et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357: 1810–20.CrossRefGoogle ScholarPubMed
Kodera, Y, Yamamura, Y, Torii, A et al. (1996) Postoperative staging of gastric carcinoma. A comparison between the UICC stage classification and the 12th edition of the Japanese General Rules for Gastric Cancer Study. Scand J Gastroenterol. 31: 476–80.CrossRefGoogle ScholarPubMed
Sobin, L, Wittekind, C (2002) TNM Classification of Malignant Tumours. Hoboken, NJ: Wiley-Liss.Google Scholar
Tsujimoto, M, Nakabayashi, K, Yoshidome, K et al. (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 13: 4807–16.CrossRefGoogle ScholarPubMed
Taniyama, K, Motoshita, J, Sakane, J et al. (2006) Combination analysis of a whole lymph node by one-step nucleic acid amplification and histology for intraoperative detection of micrometastasis. Pathobiology. 73: 183–91.CrossRefGoogle ScholarPubMed
Siewert, JR, Kestlmeier, R, Busch, R et al. (1996) Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg. 83:1144–7.CrossRefGoogle ScholarPubMed
Cai, J, Ikeguchi, M, Maeta, M, Kaibara, N (2000) Micrometastasis in lymph nodes and microinvasion of the muscularis propria in primary lesions of submucosal gastric cancer. Surgery. 127: 32–9.CrossRefGoogle ScholarPubMed
Maehara, Y, Oshiro, T, Endo, K et al. (1996) Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery. 119: 397–402.CrossRefGoogle Scholar
Yonemura, Y, Endo, Y, Hayashi, I, Kawamura, T, Yun, HY, Bandou, E (2007) Proliferative activity of micrometastases in the lymph nodes of patients with gastric cancer. Br J Surg. 94: 731–6.CrossRefGoogle ScholarPubMed
Arigami, T, Natsugoe, S, Uenosono, Y et al. (2006) Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg. 243: 341–7.CrossRefGoogle ScholarPubMed
Morgagni, P, Saragoni, L, Scarpi, E et al. (2003) Lymph node micrometastases in early gastric cancer and their impact on prognosis. World J Surg. 27: 558–61.CrossRefGoogle ScholarPubMed
Kim, JH, Park, JM, Jung, CW et al. (2008) The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. J Surg Oncol. 97: 125–30.CrossRefGoogle ScholarPubMed
Wu, ZY, Li, JH, Zhan, WH, He, YL (2006) Lymph node micrometastasis and its correlation with MMP-2 expression in gastric carcinoma. World J Gastroenterol. 12: 2941–4.CrossRefGoogle ScholarPubMed
Okada, Y, Fujiwara, Y, Yamamoto, H et al. (2001) Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Cancer. 92: 2056–64.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Siewert, JR, Sendler, A (2000) Potential and futility of sentinel node detection for gastric cancer. Recent Results Cancer Res. 157: 259–69.CrossRefGoogle ScholarPubMed
Miyashiro, I, Takachi, K, Doki, Y et al. (2005) When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant?World J Surg. 29: 1131–4.CrossRefGoogle ScholarPubMed
Fujimura, T, Ohta, T, Kitagawa, H et al. (1998) Trypsinogen expression and early detection for peritoneal dissemination in gastric cancer. J Surg Oncol. 69: 71–5.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Mori, N, Oka, M, Hazama, S et al. (2000) Detection of telomerase activity in peritoneal lavage fluid from patients with gastric cancer using immunomagnetic beads. Br J Cancer. 83: 1026–32.CrossRefGoogle ScholarPubMed
Yonemura, Y, Fujimura, T, Ninomiya, IT et al. (2001) Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res. 7: 1647–53.Google ScholarPubMed
Kodera, Y, Nakanishi, H, Ito, S et al. (2006) Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup. J Am Coll Surg. 202: 231–6.CrossRefGoogle ScholarPubMed
Ito, S, Nakanishi, H, Kodera, Y, Mochizuki, Y, Tatematsu, M, Yamamura, Y (2005) Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer. 93: 986–92.CrossRefGoogle ScholarPubMed
Sakakura, C, Hagiwara, A, Nakanishi, M et al. (2002) Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer. 87: 1153–61.CrossRefGoogle ScholarPubMed
Maehara, Y, Hasuda, S, Abe, T et al. (1998) Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res. 4: 2129–34.Google ScholarPubMed
Macadam, R, Sarela, A, Wilson, J, MacLennan, K, Guillou, P (2003) Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol. 29: 450–4.CrossRefGoogle ScholarPubMed
Oki, E, Kakeji, Y, Baba, H et al. (2007) Clinical significance of cytokeratin-positive cells in bone marrow of gastric cancer patients. J Cancer Res Clin Oncol. 133: 995–1000.CrossRefGoogle ScholarPubMed
Yie, SM, Lou, B, Ye, SR et al. (2008) Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 15:2934–42.CrossRefGoogle Scholar
Mimori, K, Fukagawa, T, Kosaka, Y et al. (2008) A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol. 31: 3073–82.Google Scholar
Huber, MA, Kraut, N, Beug, H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17: 548–58.CrossRefGoogle ScholarPubMed
Becker, KF, Rosivatz, E, Blechschmidt, K, Kremmer, E, Sarbia, M, Hofler, H (2007) Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs. 185: 204–12.CrossRefGoogle ScholarPubMed
Washington, K, Chiappori, A, Hamilton, K et al. (1998) Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol. 11: 805–13.Google ScholarPubMed
Koyama, T, Yashiro, M, Inoue, T, Nishimura, S, Hirakawa, YSCK (2000) TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol. 16: 355–62.Google ScholarPubMed
Matsuoka, T, Hirakawa, K, Chung, YS et al. (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis. 16: 381–8.CrossRefGoogle ScholarPubMed
Lee, JM, Dedhar, S, Kalluri, R, Thompson, EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 172: 973–81.CrossRefGoogle ScholarPubMed
Yamamoto, H, Horiuchi, S, Adachi, Y et al. (2004) Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis. 25: 325–32.CrossRefGoogle ScholarPubMed
Ajisaka, H, Yonemura, Y, Miwa, K (2004) Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology. 51: 900–5.Google ScholarPubMed
Kitoh, T, Yanai, H, Saitoh, Y et al. (2004) Increased expression of matrix metalloproteinase-7 in invasive early gastric cancer. J Gastroenterol. 39: 434–40.CrossRefGoogle ScholarPubMed
Horiuchi, S, Yamamoto, H, Min, Y, Adachi, Y, Itoh, F, Imai, K (2003) Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol. 200: 568–76.CrossRefGoogle ScholarPubMed
Inoue, T, Yashiro, M, Nishimura, S et al. (1999) Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med. 4: 73–7.Google ScholarPubMed
Ito, R, Kitadai, Y, Kyo, E et al. (1993) Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res. 53: 4102–6.Google ScholarPubMed
Stacker, SA, Caesar, C, Baldwin, ME et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 7: 186–91.CrossRefGoogle ScholarPubMed
Shimizu, K, Kubo, H, Yamaguchi, K et al. (2004) Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 95: 328–33.CrossRefGoogle ScholarPubMed
Mashino, K, Sadanaga, N, Yamaguchi, H et al. (2002) Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62: 2937–41.Google ScholarPubMed
Schmausser, B, Endrich, S, Brandlein, S et al. (2005) The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritis, gastric carcinoma and its precursor lesions and up-regulated by H. pylori. Clin Exp Immunol. 139: 323–7.CrossRefGoogle ScholarPubMed
Tahara, E (1993) Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol. 119:265–72.CrossRefGoogle ScholarPubMed
Kuniyasu, H, Yasui, W, Kitadai, Y, Yokozaki, H, Ito, H, Tahara, E (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 189: 227–32.CrossRefGoogle ScholarPubMed
Tendo, M, Yashiro, M, Nakazawa, K et al. (2006) A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett. 244: 247–51.CrossRefGoogle ScholarPubMed
Yano, T, Doi, T, Ohtsu, A et al. (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 15: 65–71.Google ScholarPubMed
Guilford, P, Hopkins, J, Harraway, J et al. (1998) E-cadherin germline mutations in familial gastric cancer. Nature. 392: 402–5.CrossRefGoogle ScholarPubMed
Yamamoto, H, Perez-Piteira, J, Yoshida, T et al. (1999) Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology. 116: 1348–57.CrossRefGoogle ScholarPubMed
Beghelli, S, Manzoni, G, Barbi, S et al. (2006) Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery. 139: 347–56.CrossRefGoogle ScholarPubMed
Tokunaga, M, Land, CE (1998) Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Cancer Epidemiol Biomarkers Prev. 7: 449–50.Google ScholarPubMed
Wu, MS, Shun, CT, Wu, CC et al. (2000) Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology. 118: 1031–8.CrossRefGoogle Scholar
Yoshikawa, T, Tsuburaya, A, Kobayashi, O, Sairenji, M, Motohashi, H, Noguchi, Y (2001) Should scirrhous gastric carcinoma be treated surgically? Clinical experiences with 233 cases and a retrospective analysis of prognosticators. Hepatogastroenterology. 48: 1509–12.Google Scholar
Fujimura, T, Yonemura, Y, Muraoka, K et al. (1994) Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 18: 150–5.CrossRefGoogle ScholarPubMed
Iqubal, S, Goldman, B, Lenz, H, Fenoglio-Preiser, C, Blanke, C (2007) A Phase II study of GW572016 (lapatinib) as first-line therapy in patients (pts) with advanced or metastatic gastric cancer. Int J Clin Oncol. 102: 500–5.Google Scholar
Doi, T, Koizumi, W, Siena, S, Cascinu, S, Ohtsu, A, Michael, M (2003) Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. In Proceedings of Am Soc Clin Oncol. 60:22.Google Scholar
Dragovich, T, McCoy, S, Fenoglio-Preiser, CM et al. (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 24: 4922–7.CrossRefGoogle ScholarPubMed
Pinto, C, Di Fabio, F, Siena, S et al. (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 18: 510–7.CrossRefGoogle ScholarPubMed
Lordick, F, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Woll, E, Decker, T (2007) Cetuximab plus weekly ozaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter Phase II study study of the AIO upper GI study group. J Clin Oncol. 102: 400–10.Google Scholar
Bang, YJ, Cutsem, E, Feyereislova, A, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet, 376: 687–97.Google Scholar
Jhawer, MP, Kindler, HL, Wainberg, ZA, et al. (2008) Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer: Interim results of a multicenter phase II study. J Clin Oncol, 26: 15S Part I of II, 4572.CrossRefGoogle Scholar
Hirashima, Y, Yamada, Y, Matsubara, J, et al. (2009) Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci 100: 310–15.CrossRef
Kang, Y, Ohtsu, A, Cutsem, E, et al. (2010) AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. J Clin Oncol, 28: 18S Part II of II, LBA4007.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×